US2006089313A1PendingUtilityA1
Methods and compositions for ameliorating the undesirable effects of chemotherapy
Est. expiryNov 29, 2021(expired)· nominal 20-yr term from priority
A61K 38/04A61P 35/00A61K 31/7076A61K 31/519A61K 31/198A61P 43/00A61P 39/00A61K 31/197A61K 45/06A61K 31/195A61K 38/05A61K 33/243
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at least one adverse effect of chemotherapy, the methods each comprising the step of administering to a subject undergoing chemotherapy an amount of a chemoprotectant composition that is effective to ameliorate at least one adverse effect of the chemotherapy.
Claims
exact text as granted — not AI-modified1 - 5 . (canceled)
6 . A method of ameliorating at least one adverse effect of chemotherapy, the method comprising the step of administering to a subject undergoing chemotherapy an amount of a chemoprotectant composition that is effective to ameliorate at least one adverse effect of the chemotherapy, said chemoprotectant composition comprising a chemoprotectant selected from the group consisting of: L-methionine, N-acetyl-DL-methionine, S-adenosylmethionine, cysteine, homocysteine, cystathione, cysteamine, N-acetylcysteine, glutathione, glutathione ethylester, glutathione diethylester, glutathione triethylester, cysteamine, DiNAC, RibCys, RibCyst, β-LactCys, α-LactCys, MeliCys, MaltCys, CellCys, OTCA, allopurinol, 1-methylallopurinol, 2-methylallopurinol, 5-methylallopurinol, 7-methylallopurinol, 1,5-dimethylallopurinol, 2,5-dimethylallopurinol, 1,7-dimethylallopurinol, 2,7-dimethylallopurinol, 5,7-dimethylallopurinol, 2,5,7-trimethylallopurinol, 1-ethoxycarbonylallopurinol, 1-ethoxycarbonyl-5-methylallopurinol, 2-phenyl-1,2-benzoisoselenazol-3(2H)-one, and 6-diSeCD.
7 . A method of claim 6 wherein said chemoprotectant composition comprises a chemoprotectant selected from the group consisting of allopurinol, 2-phenyl-1,2-benzoisoselenazol-3(2H)-one, and N-acetylcysteine.
8 . A method of claim 6 wherein said chemoprotectant composition comprises allopurinol and 2-phenyl-1,2-benzoisoselenazol-3(2H)-one.
9 . A method of claim 8 wherein said allopurinol is administered in an amount of from 10 to 2400 mg/day, and said 2-phenyl-1,2-benzoisoselenazol-3(2H)-one is administered in an amount of from 5 to 5000 mg/day.
10 . A method of claim 6 wherein said chemoprotectant composition comprises allopurinol and N-acetylcysteine.
11 . A method of claim 10 wherein said allopurinol is administered in an amount of from 10 to 2400 mg/day, and said N-acetylcysteine is administered in an amount of from 5 to 5000 mg/day.
12 . A method of claim 6 wherein said chemoprotectant composition comprises 2-phenyl-1,2-benzoisoselenazol-3(2H)-one, and N-acetylcysteine.
13 . A method of claim 12 wherein said 2-phenyl-1,2-benzoisoselenazol-3(2H)-one is administered in an amount of from 5-5000 mg/day, and said N-acetylcysteine is administered in an amount of from 5 to 5000 mg/day.
14 - 17 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.